MiMedx (NASDAQ: MDXG) launches $40M savings plan amid Wound Care slowdown
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
MiMedx Group, Inc. launched a restructuring and cost reduction initiative to streamline operations and support future profitability. The plan targets approximately $40 million in annualized operating expense savings across the company and will result in a one-time restructuring charge of about $4 million in the second quarter of 2026.
As part of the changes, the position of Chief Operating Officer held by Ricci Whitlow was eliminated; her departure is stated as not due to a disagreement with the company. CEO Joe Capper’s base salary was reduced by 20%, while base salaries for other named executive officers were reduced by 10% through December 31, 2026.
Management notes that the Surgical business is performing well, but the Wound Care business is recovering slowly following a January 1 Medicare reimbursement reduction, prompting the decision to adjust the cost structure.
Positive
- Company targets approximately $40 million in annualized operating expense savings, which could support future margins and profitability if executed effectively.
Negative
- Management cites a slow recovery in the Wound Care business following a January 1 Medicare reimbursement reduction, indicating demand and reimbursement pressure in a key segment.
- Restructuring includes elimination of the Chief Operating Officer role and a one-time $4 million restructuring charge in Q2 2026, reflecting operational disruption and near-term costs.
Insights
MiMedx cuts costs by $40M after slow Wound Care recovery.
MiMedx is undertaking a broad restructuring, eliminating the COO role and reducing executive salaries while targeting about $40 million in annualized expense savings. Management links these actions to slow recovery in its Wound Care business after a January 1 Medicare reimbursement reduction.
The company expects a one-time restructuring charge of roughly $4 million in Q2 2026. While such savings can support margins and future profitability, they also indicate pressure in a key business line and a need to reset the cost base.
Management highlights that the Surgical business continues to flourish and merits further investment, while Wound Care and the broader market remain sluggish. Future disclosures around first-quarter 2026 results and commentary on this reorganization will clarify how effectively these cuts balance growth investment with profitability.
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Annualized cost savings: $40 million
Restructuring charge: $4 million
CEO base salary reduction: 20%
+2 more
5 metrics
Annualized cost savings
$40 million
Targeted operating expense reductions across the enterprise
Restructuring charge
$4 million
Expected one-time charge in Q2 2026
CEO base salary reduction
20%
Applies to CEO Joe Capper through December 31, 2026
Other NEO salary reduction
10%
Applies to CFO, GC/CAO, and CCO through December 31, 2026
Medicare reimbursement change date
January 1
Wound Care business affected by reimbursement reduction from this date
Key Terms
cost reduction initiative, restructuring and cost reduction initiative, restructuring charge, Medicare reimbursement reduction, +1 more
5 terms
cost reduction initiative financial
"instituted a cost reduction initiative intended to prioritize growth opportunities, streamline operations and significantly reduce operating expenses"
restructuring and cost reduction initiative financial
"MIMEDX Announces Restructuring and Cost Reduction Initiative Company Expects to Realize Annualized Savings"
restructuring charge financial
"We expect a one-time restructuring charge of approximately $4 million during the second quarter of 2026"
A restructuring charge is a one-time accounting expense a company records when it reorganizes operations—like closing facilities, laying off staff, or writing down assets—to make the business leaner or change strategy. Think of it as the short-term cost of renovating a house to lower future bills: it reduces reported profit and may use cash now, but investors watch it to judge whether the cleanup will improve future profitability or hide ongoing problems.
Medicare reimbursement reduction financial
"Wound Care business, along with the broader market, is recovering from the January 1st Medicare reimbursement reduction at a very slow rate"
forward-looking statements regulatory
"This press release includes forward-looking statements, including statements regarding our expectations"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
____________________
FORM 8-K
____________________
____________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 14, 2026
(Exact name of registrant as specified in charter)
| (State or other jurisdiction | (Commission | (IRS Employer | ||||||||||||
| of incorporation) | File Number) | Identification No.) | ||||||||||||
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (770 ) 651-9100
____________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | ||||
On April 14, 2026, MiMedx Group, Inc. (the “Company”) instituted a cost reduction initiative intended to prioritize growth opportunities, streamline operations and significantly reduce operating expenses. As part of these changes Ricci Whitlow’s position of Chief Operating Officer was eliminated and she departed from the Company immediately. Ms. Whitlow’s departure was not a result of a disagreement with the Company.
Also in connection with the Company’s cost reduction initiative, CEO Joe Capper’s base salary was reduced by 20% and the base salaries of each of the other named executive officers, CFO Doug Rice, GC/CAO William “Butch” Hulse, and CCO Kimberly Maersk-Moller, were reduced by 10%. These reductions are applicable through December 31, 2026.
| Item 7.01 | Regulation FD Disclosure | ||||
On April 16, 2026, the Company issued a press release announcing its cost reduction initiative. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference.
The information in this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Item 9.01 | Financial Statements and Exhibits | ||||
(d) Exhibits.
| Exhibit No. | Description of Exhibit | |||||||
| 99.1 | Press Release dated April 16, 2026 | |||||||
| 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. | |||||||
SIGNATURES
Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MIMEDX GROUP, INC. | ||||||||
| April 16, 2026 | By: | /s/ Doug Rice | ||||||
| Doug Rice Chief Financial Officer | ||||||||
EXHIBIT 99.1 MIMEDX Announces Restructuring and Cost Reduction Initiative Company Expects to Realize Annualized Savings of Approximately $40 Million MARIETTA, Ga., April 16, 2026 -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced a series of cost reduction initiatives intended to prioritize growth opportunities, streamline operations and significantly reduce operating expenses. As part of these changes, the position of Chief Operating Officer, held by Ricci Whitlow, has been eliminated. “On behalf of the Board and management team, I want to thank Ricci for her innumerable contributions to MIMEDX and her exceptional leadership in helping to build and scale our operations,” stated Joseph H. Capper, MIMEDX Chief Executive Officer. “Ricci joined the Company at a pivotal time in the organization’s history and successfully navigated us through several regulatory audits and product launches, all while helping us scale operations in support of our long-term growth aspirations. We are deeply grateful for Ricci’s commitment to the organization, and we wish her the very best in all future endeavors.” Mr. Capper continued, “This leadership change comes as part of a broader restructuring and cost savings initiative at MIMEDX. Over the last few months, we have conducted a detailed review of our business and supporting corporate structure. While our Surgical business continues to flourish and warrants additional investments, our Wound Care business, along with the broader market, is recovering from the January 1st Medicare reimbursement reduction at a very slow rate.” “As we entered the new year, we kept the organization resourced in the event of a rapid recovery in the Wound market. Based on first quarter market behavior, it is clear the transition is happening at a more sluggish pace, and we must now make the requisite adjustments to our cost structure to ensure the future profitability of the business. As such, we have taken steps to reduce our annual operating expenses across the enterprise by approximately $40 million. We expect a one-time restructuring charge of approximately $4 million during the second quarter of 2026 associated with these changes,” concluded Mr. Capper. The Company plans to provide additional commentary around the first quarter of 2026 operating and financial results and the impact of this reorganization during its quarterly conference call in late April. Forward Looking Statements This press release includes forward-looking statements, including statements regarding our expectations regarding the impact of our cost reduction initiatives and reimbursement changes. Additional forward- looking statements may be identified by words such as "believe," "expect," "may," "plan," “goal,” “outlook,” "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set
EXHIBIT 99.1 forth in the forward-looking statements. Any forward-looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement. About MIMEDX MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com. Contact: Matt Notarianni Investor Relations 470-304-7291 mnotarianni@mimedx.com
FAQ
What cost savings does MiMedx Group (MDXG) expect from its restructuring?
MiMedx expects to achieve approximately $40 million in annualized operating expense savings from its restructuring. These savings come from streamlining operations, eliminating the Chief Operating Officer role, and broader cost reductions across the enterprise.
Why is MiMedx implementing a cost reduction initiative in 2026?
MiMedx is cutting costs to prioritize growth areas and maintain profitability as its Wound Care business recovers slowly from a January 1 Medicare reimbursement reduction. Management reviewed its structure and decided to realign expenses with the current market environment.
How does the MiMedx restructuring affect executive compensation?
As part of the initiative, CEO Joe Capper’s base salary is reduced by 20%, while the base salaries of other named executive officers are reduced by 10%. These reductions remain in effect through December 31, 2026.
Which MiMedx business segments are most impacted by market conditions?
Management notes the Surgical business continues to flourish and warrants additional investment, while the Wound Care business and broader market are recovering slowly from the January 1 Medicare reimbursement reduction, prompting the cost structure adjustments.
What leadership change did MiMedx announce with this restructuring?
MiMedx eliminated the role of Chief Operating Officer, a position held by Ricci Whitlow, who departed the company immediately. The company states her departure was not due to a disagreement with MiMedx.